Every number on the card is either sourced below or marked as protocol — how we operationalize the source, not a trial of this product.
Honesty
Muscle, lean mass, estimates
Skeletal muscle is contractile tissue. Lean mass on a DXA scan also includes water, organs, glycogen, and other fat-free tissue. A scale cannot tell those apart. This product does not measure muscle.
Published GLP-1 nutrition advice pairs adequate protein with resistance training. Protein targets alone do not preserve muscle. We do not guarantee that hitting a gram number keeps muscle.
Not professionally endorsed. Citations are literature we operationalize — not a PivotOrder trial, not individualized medical precision, and not a guarantee of preserving muscle.
01
2025 joint clinical advisory
Four US societies — ACLM, ASN, the Obesity Medicine Association, and The Obesity Society — published nutritional priorities to support GLP-1 therapy. Adequate protein and resistance training sit together in that list. Protein without training is not a muscle-preservation protocol.
Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. 2025. Concurrent publication in Obesity, the American Journal of Clinical Nutrition, Obesity Pillars, and American Journal of Lifestyle Medicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC12304835/
02
Lean tissue as a share of weight lost — literature, not you
Incretin trials often report lean tissue at about 20–40% of weight lost. That is a published range across studies — not your personal forecast, not a kg of muscle lost from a check-in, and not a PivotOrder measurement.
Linge J, Birkenfeld AL, Neeland IJ. Muscle mass and glucagon-like peptide-1 receptor agonists: adaptive or maladaptive response to weight loss? Circulation. 2024;150:1288–1298. doi:10.1161/CIRCULATIONAHA.124.067676. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes Obes Metab. 2025. doi:10.1111/dom.16275.
03
Protein band 1.2–1.6 g/kg
The 1.2–1.6 g/kg/day band is from the 2025 joint advisory and moves only with body weight. Working increments for drug, dose-phase, or appetite are product start rules inside that band. They are not validated individualized medical precision. Week number alone does not require a new target. Actual vs adjusted body weight is still debated; a clinician-set gram target wins when one exists. We do not invent a new clinical threshold.
04
Per-meal leucine ~2.5–3 g is a check
A leucine meal check (~2.5–3 g) is a practical per-occasion literature range. Clearing leucine at one plate is not the same as hitting the day’s protein floor. Moore and colleagues showed that ~20 g of high-quality protein maximally stimulated muscle protein synthesis after resistance exercise in young men — a context that typically carries on the order of ~2.5 g leucine. That is young men after lifting, not a GLP-1 personal prescription.
Moore DR, Robinson MJ, Fry JL, et al. Ingested protein dose response of muscle and albumin protein synthesis after resistance exercise in young men. Am J Clin Nutr. 2009;89:161–168. doi:10.3945/ajcn.2008.26401. Layman DK, Anthony TG, Rasmussen BB, et al. Defining meal requirements for protein to optimize metabolic roles of amino acids. Am J Clin Nutr. 2015;101:1330S–1338S. doi:10.3945/ajcn.114.084053.
05
Tirzepatide is a dual agonist
Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist. The correct term is dual agonist, never dual inhibitor. Semaglutide is a GLP-1 receptor agonist. Both can quiet appetite. Neither licenses us to forecast your muscle.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205–216. doi:10.1056/NEJMoa2206038.
06
What still needs expert review
Residual gaps — not professionally endorsed: whether 1.2–1.6 g/kg should use actual, adjusted, or ideal weight for a given body; how to individualize protein in CKD or other disease; whether any leucine threshold generalizes from young lifters to incretin users; and any personal lean-mass or muscle-loss number. Not professionally endorsed. Citations are literature we operationalize — not a PivotOrder trial, not individualized medical precision, and not a guarantee of preserving muscle.
